Unverified50% confidenceDecision RuleExact time

Including eating disorder-related symptoms in the pharmacovigilance scope of GLP-1 drugs means embedding psychological assessment into prescribing, follow-up, and data reporting.

1

Sources

50%

Confidence

Long-term

Relevance

10/30/2026

First Seen

Sources

GLP-1 Weight-Loss Drugs and Rising Eating Disorders: Cure or Catalyst?

Related Entities

GLP-1 Receptor Agonistconcept 进食障碍concept Pharmacovigilanceconcept

Related Claims

UnverifiedClinical trials of most GLP-1 drugs did not include eating disorder patients in their primary endpoints, meaning safety data for the drugs in this population are limited.73% similar

Cite This Claim

Stable URI

https://kongchang.com/claim/1115053

API

curl https://kongchang.com/api/v1/knowledge/claims/1115053

MCP

get_claim(id=1115053)